{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007181","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2026-09-16T11:00:44+00:00","discovered_at":"2026-09-16T11:05:00.242097+00:00","generated_at":"2026-09-16T11:05:15.201537+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Xenetic to acquire Santersus in all-stock deal; combined company to trade as SNTS","bullets":["Share exchange: Xenetic acquires all Santersus shares; Santersus holders to own ~85% of combined company.","Combined company to rename Santersus Bio, Inc. and list on Nasdaq under ticker SNTS.","Post-close board: 8 members (6 Santersus, 2 Xenetic); Santersus CEO James Ladtkow to lead.","Deal includes $500,000 termination fee and 180-day lock-up for officers/directors/stockholders.","Pipeline: four first-in-class programs incl. sepsis and SLE with FDA Breakthrough Device Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007181","json":"https://secwatch.observer/filing/0001683168-26-007181.json","markdown":"https://secwatch.observer/filing/0001683168-26-007181.md","text":"https://secwatch.observer/filing/0001683168-26-007181.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/0001683168-26-007181-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316826007181/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-16T11:05:15.201537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}